Recent advances in understanding the molecular basis of Paget disease of bone

Journal of Clinical Pathology

Volumn 63, Issue 3, 2010, Pages 199-203

  Goode, A ^a   Layfield, Robert ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P62; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

APOPTOSIS; AUTOPHAGY; BONE TURNOVER; ENVIRONMENTAL FACTOR; GENE MUTATION; HEREDITY; HUMAN; MOLECULAR GENETICS; NONHUMAN; OSTEOCLAST; PAGET BONE DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; AUTOPHAGY; DISEASE MODELS, ANIMAL; ENVIRONMENT; HUMANS; MICE; MUTATION; NF-KAPPA B; OSTEITIS DEFORMANS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION;

EID: 77749301510     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.064428     Document Type: Review

References (55)

1. Kanis JA. Pathophysiology and treatment of Paget's disease of bone. London: Martin Dunitz, 1992.
2. Cundy T, Bolland M. Paget disease of bone. Trends Endocrinol Metab 2008;19:246-53.
3. Ralston SH. Pathogenesis of Paget's disease of bone. Bone 2008;43:819-25.
4. Cundy T. Is the prevalence of Paget's disease of bone decreasing? J Bone Miner Res 2006;21(Suppl 2):9-13.
5. Bastin S, Bird H, Gamble G, et al. Paget's disease of bone e becoming a rarity? Rheumatology (Oxford) 2009;48:1232-5.
6. Reddy SV, Menaa C, Singer FR, et al. Cell biology of Paget's disease. J Bone Miner Res 1999;14(Suppl 2):3-8.
7. Hiruma Y, Kurihara N, Subler MA, et al. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet 2008;17:3708-19.
8. Seitz S, Priemel M, Zustin J, et al. Paget's disease of bone: histologic analysis of 754 patients. J Bone Miner Res 2009;24:62-9.
9. Layfield R. The molecular pathogenesis of Paget disease of bone. Expert Rev Mol Med 2007;9:1-13.
10. Layfield R, Shaw B. Ubiquitin-mediated signalling and Paget's disease of bone. BMC Biochem 2007;8(Suppl 1):S5.
11. Hurley JH, Lee S, Prag G. Ubiquitin-binding domains. Biochem J 2006;399:361-72.
12. Cavey JR, Ralston SH, Hocking LJ, et al. Loss of ubiquitin-binding associated with Paget's disease of bone p62 (SQSTM1) mutations. J Bone Miner Res 2005;20:619-24.
13. Cavey JR, Ralston SH, Sheppard PW, et al. Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone. Calcif Tissue Int 2006;78:271-7.
14. Rhodes EC, Johnson-Pais TL, Singer FR, et al. Sequestosome 1 (SQSTM1) mutations in Paget's disease of bone from the United States. Calcif Tissue Int 2008;82:271-7.
15. Chung PY, Beyens G, Guañabens N, et al. Founder effect in different European countries for the recurrent P392L SQSTM1 mutation in Paget's Disease of Bone. Calcif Tissue Int 2008;83:34-42.
16. Lucas GJ, Hocking LJ, Daroszewska A, et al. Ubiquitin-associated domain mutations of SQSTM1 in Paget's disease of bone: evidence for a founder effect in patients of British descent. J Bone Miner Res 2005;20:227-31.
17. Falchetti A, Di Stefano M, Marini F, et al. Genetic epidemiology of Paget's disease of bone in Italy: sequestosome1/p62 gene mutational test and haplotype analysis at 5q35 in a large representative series of sporadic and familial Italian cases of Paget's disease of bone. Calcif Tissue Int 2009;84:20-37.
18. Hocking LJ, Lucas GJ, Daroszewska A, et al. Novel UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 2004;19:1122-7.
19. Najat D, Garner T, Hagen T, et al. Characterization of a non-UBA domain missense mutation of sequestosome 1 (SQSTM1) in Paget's disease of bone. J Bone Miner Res 2009;24:632-42.
20. Rea SL, Walsh JP, Ward L, et al. Sequestosome 1 mutations in Paget's disease of bone in Australia: prevalence, genotype/phenotype correlation, and a novel non-UBA domain mutation (P364S) associated with increased NF-kappaB signaling without loss of ubiquitin binding. J Bone Miner Res 2009;24:1216-23.
21. Merchant A, Smielewska M, Patel N, et al. Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget's disease of bone. J Bone Miner Res 2009;24:484-94.
22. Matthews BG, Naot D, Bava U, et al. Absence of somatic SQSTM1 mutations in Paget's disease of bone. J Clin Endocrinol Metab 2009;94:691-4.
23. Lucas GJ, Riches PL, Hocking LJ, et al. Identification of a major locus for Paget's disease on chromosome 10p13 in families of British descent. J Bone Miner Res 2008;23:58-63.
24. Albagha OME, Visconti MR, Alonso N, et al. Identification of novel genetic variants that predispose to Paget's disease of bone by genome wide association. Bone 2009;44(Suppl 2):224-5.
25. Matthews BG, Afzal MA, Minor PD, et al. Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease. J Clin Endocrinol Metab 2008;93:398-401.
26. Durán A, Serrano M, Leitges M, et al. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 2004;6:303-9.
27. Chamoux E, Couture J, Bisson M, et al. The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts. Mol Endocrinol 2009;23:1668-80.
28. Wooten MW, Geetha T, Seibenhener ML, et al. The p62 scaffold regulates nerve growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination. J Biol Chem 2005;280:35625- 9.
29. Martin P, Diaz-Meco MT, Moscat J. The signaling adapter p62 is an important mediator of T helper 2 cell function and allergic airway inflammation. EMBO J 2006;25:3524-33.
30. Jin W, Chang M, Paul EM, et al. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest 2008;118:1858-66.
31. Sundaram K, Shanmugarajan S, Sudhaker Rao D, et al. Functional Role of p62 (SQSTM1) interaction with deubiquitinating enzyme CYLD in Paget's disease of bone. J Bone Miner Res 2009;24(Suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid= 4746eb24-7fa9-4945-8a0b-cb2d2a6a6e26 (accessed 5 October 2009).
32. Nagy ZB, Gergely P, Donáth J, et al. Gene expression profiling in Paget's disease of bone: upregulation of interferon signalling pathways in pagetic monocytes and lymphocytes. J Bone Miner Res 2008;23:253-9.
33. Naot D, Bava U, Matthews B, et al. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. J Bone Miner Res 2007;22:298-309.
34. Marshall MJ, Evans SF, Sharp CA, et al. Increased circulating Dickkopf-1 in Paget's disease of bone. Clin Biochem 2009;42:965-9.
35. Shvets E, Fass E, Scherz-Shouval R, et al. The N-terminus and Phe52 residue of LC3 recruit p62/SQSTM1 into autophagosomes. J Cell Sci 2008;121:2685-95.
36. Kim PK, Hailey DW, Mullen RT, et al. Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes. Proc Natl Acad Sci U S A 2008;105:20567-74.
37. Kirkin V, McEwan DG, Novak I, et al. A role for ubiquitin in selective autophagy. Mol Cell 2009;34:259-69.
38. Pohl C, Jentsch S. Midbody ring disposal by autophagy is a post-abscission event of cytokinesis. Nat Cell Biol 2009;11:65-70.
39. Mathew R, Karp CM, Beaudoin B, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009;137:1062-75.
40. Pursiheimo JP, Rantanen K, Heikkinen PT, et al. Hypoxia-activated autophagy accelerates degradation of SQSTM1/p62. Oncogene 2009;28:334-44.
41. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009;115:1531-43.
42. Klionsky DJ, Abeliovich H, Agostinis P, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008;4:51-75.
43. Collet C, Michou L, Audran M, et al. Paget's disease of bone in the French population: novel SQSTM1 mutations, functional analysis, and genotype-phenotype correlations. J Bone Miner Res 2007;22:310-7.
44. Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through cellular self-digestion. Nature 2008;451:1069-75.
45. Zhang P, Chan J, Dragoi AM, et al. Activation of IKK by thymosin alpha1 requires the TRAF6 signalling pathway. EMBO Rep 2005;6:531-7.
46. Korolchuk VI, Mansilla A, Menzies FM, et al. Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 2009;33:517-27.
47. Jin Z, Li Y, Pitti R, et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009;137:721-35.
48. Kurihara N, Hiruma Y, Zhou H, et al. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest 2007;117:133-42.
49. Daroszewska A, Rojas J, Rose L, et al. Knock-in of the P392L mutation of SQSTM1 causes a phenotype similar to Paget's disease in mice. Calcif Tissue Int 2008;82:S34-5.
50. Daroszewska A, Van't Hof R, Rose L, et al. The P392L mutation of SQSTM1 causes a Paget's disease-like phenotype in mice. J Bone Miner Res 2009;24(Suppl 1). http://www.asbmr.org/Meetings/ AnnualMeeting/AbstractDetail.aspx?aid=95738926-f13a-4dfc-af95-b58f6759122e (accessed 5 October 2009).
51. Daroszewska A, Rose L, Rose K, et al. Development of a novel animal model for the syndrome of inclusion body myopathy, Paget's disease and fronto-temporal dementia. Abstract OP27 presented at ECTS 36th Symposium on Calcified Tissues, Vienna, May 2009. 〈http://abstract.mci-group.com/cgi- bin/mc/printabs.pl?APP=ECTS2009-abstract&TEMPLATE=&keyf= 0497&showHide=show&client=〉. (accessed 5 October 2009).
52. Taylor MP, Jackson WT. Viruses and arrested autophagosome development. Autophagy 2009;5:870-1.
53. Ishii T, Yanagawa T, Yuki K, et al. Low micromolar levels of hydrogen peroxide and proteasome inhibitors induce the 60-kDa A170 stress protein in murine peritoneal macrophages. Biochem Biophys Res Commun 1997;232:33-7.
54. Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet 2008;372:155-63.
55. Langston AL, Campbell MK, Fraser WD, et al. Randomised trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res Published Online First: 6 July 2009. doi:10.1359/jbmr.090709.